CEACAM6 and pancreatic adenocarcinoma: CEACAM6 expression was detected in 92%, in a study including patients with pancreatic adenocarcinoma, while negative CEACAM6 expression was observed in patients with an absence of lymph node metastases and longer postoperative survival [75].